睿昂基因(688217.SH):公司預計白血病15種融合基因試劑盒替換3種融合基因試劑盒的替換率在60%-70%
格隆匯6月21日丨有投資者向睿昂基因(688217.SH)提問:請問血病15種融合基因試劑盒替代白血病3種融合基因試劑盒的進展如何?公司預計會達到多少的替代率呢?
睿昂基因回覆:白血病15種融合基因是包含原有的白血病3種融合基因,3種融合基因大概佔可以檢出的融合基因的50%,15種融合基因佔可以檢出的融合基因的90%以上,用15種融合基因去替代3種融合基因,能發現除了3種以外的融合基因,避免患者重複抽骨髓。如果推廣順利,15種融合基因有望完全替代3種融合基因。但是考慮到一些患者經濟因素,公司預計白血病15種融合基因試劑盒替換3種融合基因試劑盒的替換率在60%-70%之間。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.